Introduction: The aim of this study was to validate stage groupings in the eighth edition of the TNM classification in an independent Chinese cohort.
Introduction
The TNM classification provides a uniform nomenclature describing the anatomic extent of cancer. This classification aids effective communication among oncology health professionals and plays an important role in the planning of treatment, prediction of survival, and implementation of clinical trials. 1 Successive revisions of the TNM stage classification for lung cancer have addressed shortcomings identified by the lung cancer community since its establishment in 1966. 2 In 2015 and 2016, the International Association for Lung Cancer Study (IASLC) Staging and Prognostic Factors Committee (SPFC) published a series of articles to inform the eighth edition of the anatomic classification of lung cancer. [3] [4] [5] [6] [7] [8] [9] [10] [11] The eighth edition of the TNM classification for lung cancer was developed on the basis of the new IASLC database, which contains information on 94,708 patients worldwide with newly diagnosed lung cancer. In the database, despite the inclusion of a large number of patients from Asia (mainly from Japan), only 790 patients were included from the People's Republic of China. 12 In the People's Republic of China, there were more than 700,000 newly diagnosed lung cancer cases in 2015. 13 The People's Republic of China is the country with the largest number of patients with lung cancer in the world. Despite being of the same ethnic group as Japanese patients, Chinese patients show great differences in their clinicopathological characteristics and prognoses.
14 Thus, patients from the People's Republic of China might not be well represented by the new IASLC database. Hence, although the external validation results based on the National Cancer Database by the IASLC SPFC have been issued, 15 a robust external validation of the new TNM classification among a large Chinese cohort is still urgently needed. It is of significance to validate the eighth edition of the TNM classification in a large Chinese patient cohort.
Patients and Methods

Patients
We retrospectively reviewed the medical records of patients with pathologically diagnosed stage IA to IIIA (seventh edition of the TNM) NSCLC who underwent surgical resection at the departments of thoracic surgery of Peking University People's Hospital and Fudan University Zhongshan Hospital between January 2005 and December 2012. In addition, the following exclusions were made: patients receiving preoperative therapy (yp-stage cases) or undergoing resection for a recurrent lung cancer (r-stage cases). Perioperative deaths within 30 days were excluded from the long-term survival analysis. Patients without follow-up information were also excluded. All patients received surgical treatment alone or combined with chemotherapy alone or with radiotherapy. The study involved no patients who were also included in the IASLC database. Experienced surgeons reviewed the clinical and pathological data and restaged all patients according to the proposals of the eighth edition of the TNM classification for lung cancer.
Because no human subjects were involved in the study and only de-identified data were used, ethical review and informed consent were waived by the institutional review board of Peking University People's Hospital.
Follow-up
Patients were examined every 6 months during the first 2 years and annually thereafter. The follow-up protocol included a physical examination, chest computed tomography (CT) scan, and abdominal ultrasound. Bone scintigraphy and brain magnetic resonance imaging (MRI) were performed when relative symptoms appeared. Recurrence was confirmed mainly by radiological examinations, including chest CT, positron emission tomography/CT, brain MRI, bone scintigraphy, and abdominal MRI and sometimes by biopsy if necessary.
Statistical Analysis
Overall survival (OS) was defined as the period from the day of surgery to the day of death from any cause. Recurrence-free survival (RFS) was defined as the period from the day of surgery to the day of recurrence or death from any cause. Kaplan-Meier curves were generated to provide estimates for OS and RFS. A log-rank test was used to compare the survival of adjacent stage groupings. Cox regression analyses, as suggested by the IASLC SPFC, were performed with the SAS System for Windows, version 9.4 (SAS Institute Inc., Cary, NC) to adjust for baseline factors (age, sex, and histologic type) and to calculate the hazard ratios (HRs) between adjacent stage group categories. The Cox regression analyses were also stratified by the extent of resection (sublobar resection vs. others). As recommended by the IASLC SPFC, the R 2 measure was considered the best metric to assess the discrimination of the classification. The R 2 measure can be used as a measure of the degree to which the observed prognoses are predicted by the stage classification.
16 R 2 was calculated using the statistical package R, version 3.2.4 (R Foundation for Statistical Computing, Vienna, Austria). All statistical tests were two sided and used an a value equal to a 0.05 level of significance.
Results
A total of 3929 patients who underwent surgical resection for p-stage IA to IIIA (seventh edition of the TNM) NSCLC were identified; 72 patients receiving preoperative treatment, six patients undergoing resection for recurrent tumors, 30 patients experiencing perioperative deaths, and 222 patients without followup information were excluded. A total of 3599 patients, including 984 from Peking University People's Hospital and 2651 from Fudan University Zhongshan Hospital, were included in the final analysis. The median follow-up time for all patients was 48.7 months (interquartile range [IQR] 30.0-68.6). The demographics and characteristics of the study cohort are summarized in Table 1 According to the eighth edition of the TNM classification, all stage groupings were ordered with a 5-year OS rate ranging from 99.2% for stage IA1 to 26.1% for stage IIIB. The step-deteriorated 5-year RFS rate ranged from 98.4% for stage IA1 to 17.3% for stage IIIB. In our study, the prognosis of each stage grouping was better than in the IASLC database, especially in the early stages.
The results of the Cox regression models adjusted for age (70 years vs. <70 years), sex (female vs. male), and histologic type (adenocarcinoma vs. others) and stratified by the extent of resection (sublobar resection vs. others) are shown in Table 3 . According to the seventh edition of the TNM classification, the difference between stage IIA vs. IIB was not significant and the HR was 1.021 for OS and 1.101 for RFS. According to the eighth edition, stage IA3 patients did not demonstrate significantly better survival than stage IB patients, but the HRs were still less than 1. The other differences between adjacent stage groupings by the seventh and eighth editions of the TNM classification were all significant. Similar findings were observed in IA  IB  IIA  IIB  IIIA  Total   IA1  129  0  0  0  0  129  IA2  351  0  0  0  0  351  IA3  270  0  0  0  0  270  IB  0  1122  0  3  0  1125  IIA  0  196  0  2  0  198  IIB  0  0  504  78  0  582  IIIA  0  0  0  172  592 In some patients of certain stage groupings by the seventh edition of the TNM classification, stage migration occurred with application of the new edition of the TNM classification, but the others remained the same. We determined whether the two types of patients had different prognoses. Table 4 shows the 5-year survival rates of all subsets and the results of pairwise comparisons of patients with vs. those without stage migration using Cox regression models adjusted for age, sex and histologic type. 
Discussion
The fundamental function of the TNM classification is to provide a consistent and reproducible description of tumor extent, although it can also provide a prediction of survival to some degree. It has been an essential component of patient treatment, research, and cancer control for lung cancer. The IASLC proposed the eighth edition of the TNM classification for lung cancer in the past 2 years. With only a small number of Chinese patients included in the new IASLC database, the applicability of the new TNM classification in the People's Republic of China is unknown. Additionally, because of the lack of robust external validation based on a large Chinese cohort, extrapolation of the new staging system has not been fully established in the People's Republic of China. The present study provides external validation of the stage groupings of the new system in a large cohort of Chinese patients who were surgically treated.
Step degradation and evident separation of survival curves of stage groupings according to the eighth edition of the TNM classification were generally observed; however, the survival curves of stage IA3 and stage IB patients were similar. The significant differences in comparisons between adjacent stage groupings continued after adjusting for other confounding variables. This finding validated the prognostic discrimination of the new staging system. Additionally, the finding that patients with and without stage migration showed distinctive prognoses for stage IB and IIIA of the seventh edition of the TNM classification validated the rationale of the stage shift.
Despite the observed better discrimination of the new staging system, the proportional distribution of each stage grouping should be noted. In the previous staging system, a small proportion of stage IIB was noted in several external validation studies after the seventh stage system was proposed. In the new system, as demonstrated in Figure 1 , the proportion of stage IIB has increased as a result of stage shifting of stage IIA patients in the seventh system. [17] [18] [19] However, the proportion of stage IIA patients has decreased to 5.5%, which is much smaller than the proportion of the other stage groupings. This finding was not due to a selection bias caused by the homogeneity of the study population, in which only patients who received surgical treatment were included. On the basis of the definition in the eighth staging system, stage IIA disease primarily included lung cancer tumors of 4 cm to 5 cm with negative lymph nodes. 6 It could be anticipated that fewer patients would be included in this stage relative to the other stage groupings because the chance of lymph node metastasis increases with the increasing diameter of the tumor. 20, 21 
<0.001
Note: Adjusted for age (70 years vs. <70 years), sex, and histologic diagnosis (adenocarcinoma vs. others) and stratified by the extent of resection (sublobar resection vs. others).
OS, overall survival; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval.
Stage reassignment with the implementation of the new TNM classification will have a substantial impact on future revisions of clinical guidelines. The statements of current guidelines should be revised because the stage groupings in the new TNM classification do not refer to the same patient cohorts as before. The applicability of operation and adjuvant chemotherapy are the main concerns for thoracic surgeons.
The long-term follow-up of the CALGB 9633 study did not demonstrate a significant survival benefit for adjuvant chemotherapy for stage IB (seventh edition of the TNM) patients with a tumor size 4 cm or larger. 22 However, retrospective studies showed that adjuvant chemotherapy was associated with improved survival in this group of patients. 23, 24 The guidelines of the National Comprehensive Cancer Network recommended a tumor size larger than 4 cm as a high-risk factor for stage IB (seventh edition of the TNM) patients when considering adjuvant chemotherapy, 25 whereas the guidelines of the American College of Chest Physicians did not recommended adjuvant chemotherapy for this patient group. 26 The debate regarding adjuvant chemotherapy for stage IB (seventh edition of the TNM) patients with a tumor size of more than 4 cm has not been resolved. When the eighth edition of the TNM classification is applied, stage IB (seventh edition of the TNM) patients with a tumor size of more than 4 cm are upstaged to stage IIA and all stage IIA patients (seventh edition of the TNM) are upstaged to stage IIB. The statements of the guidelines regarding adjuvant chemotherapy may be revised accordingly.
For stage IIIA patients (seventh edition of the TNM) with pathologically documented N2 lymph nodes metastasis, chemotherapy or concurrent chemoradiotherapy has been recommended as the initial treatment. 25, 27, 28 However, the benefit of surgery after induction therapy remains controversial because the published trials, including EORTC-08941, INT0139, and ESPATUE, have demonstrated that surgery did not improve the OS of stage IIIA (N2) patients after initial therapy compared with radiotherapy. [29] [30] [31] Surgery was associated with a prolonged progression-free survival, according to the results of the INT0139 trial. Further analysis showed that OS was improved in patients who underwent lobectomy compared with in matched patients who received radiotherapy. 30 The current National Comprehensive Cancer Network guidelines recommended surgery as an alternative treatment for these patients. 25 In the new TNM classification, except for patients downstaged from T3 to T2 on the basis of the descriptors of atelectasis/pneumonitis and distance to the carina, T2b-3N2M0 (seventh TNM) patients are upstaged from IIIA to IIIB. Stage IIIB (seventh edition of the TNM) patients are excluded from indications of surgery according to the statements of the current guidelines. Therefore, the statements of the guidelines addressing this issue should also be revised.
With the increasing application of targeted therapy, improved survival of patients with certain gene mutations or gene fusions has been observed. 32 There are increasing requests to include the genotype of the tumor in the next TNM classification system. However, it is important to recognize that the TNM classification is essentially a description of the anatomic extent of the tumor. Stage classification and prognosis prediction are two fundamentally distinct processes. Like many other nonanatomic prognostic factors, such as age, sex, and histologic type, the genotype of the tumor might determine the prognosis of patients with NSCLC to some extent, but it should not be included in the TNM staging system.
Our study was conducted and reported following the suggestions by the IASLC SPFC. 16 Our study utilized a large independent database, and none of the patients in our study were also included in the IASLC database. We reported the number of cases and events by stage groupings. Additionally, we reported on the follow-up information, ordering, homogeneity, and discrimination. Differences between subgroups were found to be consistent in the R-any cohort and R0 cohort. Further, multivariate analyses were performed to balance confounding factors among subgroups.
We acknowledge that the current study has several limitations. First, selection and information biases are inherent in retrospective studies. Second, because all data reviewed were collected only from patients undergoing surgical treatment, the survival curves might not reflect the curves of the entire population. Finally, further analyses including other potential factors, such as comorbidities, were not performed because of differences in the inclusion criteria of these data in the two centers.
In summary, the current study validated the stage groupings in the eighth edition of the TNM classification for lung cancer in a large surgically treated cohort in the People's Republic of China. The eighth edition of the TNM classification exhibits greater discrimination than the seventh edition.
